Licensing Deal

Kali Therapeutics Named to Endpoints 11 After Sanofi Licensing Deal

San Mateo, Calif. – September 25, 2026 -- Kali Therapeutics has been named one of the 11 most promising private biotechnology companies in the 2026 Endpoints 11, a list curated annually by Endpoints News editors from hundreds of private candidates.

Kali advanced two clinical candidates and closed a Sanofi licensing deal in just over two years

Founded in July 2024, the clinical-stage biotech moved from formation to two molecules in the clinic and a worldwide partnership with Sanofi inside roughly two years. The honorees were announced Thursday, September 24, 2026, at an awards gala at The State Room in Boston.

Nanexa Secures Up to EUR 1.165B Novo Nordisk Deal for PharmaShell Tech

Uppsala – September 25, 2026 -- Nanexa AB has signed a global exclusive license and collaboration agreement with Novo Nordisk worth up to EUR 1.165 billion, granting the Danish pharmaceutical giant rights to the Swedish company's PharmaShell atomic layer deposition (ALD) drug delivery platform for peptide-based treatments in obesity, type 2 diabetes and other cardiometabolic diseases.

Novo Nordisk gains rights to up to five development programs under the deal

The agreement covers formulations targeting monthly and quarterly administration frequencies, reducing dosing burden for chronic metabolic and cardiovascular disease patients. Novo Nordisk will lead global development and commercialization across all programs, while Nanexa retains eligibility for milestone-based payments tied to development, regulatory and sales achievements.

Sobi-Innate Pharma Deal Turns Effective, Triggers $75M Payment

Stockholm – September 19, 2026 -- Swedish Orphan Biovitrum AB (Sobi) has paid Innate Pharma SA USD 75 million as their strategic oncology partnership becomes legally effective, following the expiration of antitrust waiting periods and satisfaction of other closing conditions.

Partnership clears regulatory hurdles first announced August 10, 2026

The deal, initially disclosed on August 10, 2026, grants Sobi exclusive global commercialisation rights to lacutamab pending accelerated approval, with an option to assume full global development rights if Phase 3 results are positive.